138 related articles for article (PubMed ID: 23558051)
1. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.
Despierre E; Lambrechts S; Leunen K; Berteloot P; Neven P; Amant F; O'Shannessy DJ; Somers EB; Vergote I
Gynecol Oncol; 2013 Jul; 130(1):192-9. PubMed ID: 23558051
[TBL] [Abstract][Full Text] [Related]
2. Folate Receptor Alpha Expression in Platinum Resistant/Refractory Ovarian Carcinomas and Primary Endocervical Adenocarcinomas.
Rubinsak LA; Cohen C; Khanna N; Horowitz IR; Hanley KZ
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):567-572. PubMed ID: 27941566
[TBL] [Abstract][Full Text] [Related]
3. Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type.
O'Shannessy DJ; Somers EB; Smale R; Fu YS
Int J Gynecol Pathol; 2013 May; 32(3):258-68. PubMed ID: 23518909
[TBL] [Abstract][Full Text] [Related]
4. Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers.
O'Shannessy DJ; Somers EB; Wang LC; Wang H; Hsu R
J Ovarian Res; 2015 May; 8():29. PubMed ID: 25971554
[TBL] [Abstract][Full Text] [Related]
5. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer.
Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C
Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105
[TBL] [Abstract][Full Text] [Related]
6. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.
Kurosaki A; Hasegawa K; Kato T; Abe K; Hanaoka T; Miyara A; O'Shannessy DJ; Somers EB; Yasuda M; Sekino T; Fujiwara K
Int J Cancer; 2016 Apr; 138(8):1994-2002. PubMed ID: 26595060
[TBL] [Abstract][Full Text] [Related]
7. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
Azaïs H; Queniat G; Bonner C; Kerdraon O; Tardivel M; Jetpisbayeva G; Frochot C; Betrouni N; Collinet P; Mordon S
Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.
Azaïs H; Schmitt C; Tardivel M; Kerdraon O; Stallivieri A; Frochot C; Betrouni N; Collinet P; Mordon S
Photodiagnosis Photodyn Ther; 2016 Mar; 13():130-138. PubMed ID: 26200606
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
[TBL] [Abstract][Full Text] [Related]
10. EphA8 is a prognostic marker for epithelial ovarian cancer.
Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
12. Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer.
Cybulski M; Jarosz B; Nowakowski A; Jeleniewicz W; Kutarska E; Bednarek W; Stepulak A
Anticancer Res; 2015 Mar; 35(3):1715-21. PubMed ID: 25750333
[TBL] [Abstract][Full Text] [Related]
13. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.
Crane LM; Arts HJ; van Oosten M; Low PS; van der Zee AG; van Dam GM; Bart J
Cell Oncol (Dordr); 2012 Feb; 35(1):9-18. PubMed ID: 21647742
[TBL] [Abstract][Full Text] [Related]
14. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
15. [Specific folic-acid targeted photosensitizer. The first step toward intraperitoneal photodynamic therapy for epithelial ovarian cancer].
Azaïs H; Frochot C; Grabarz A; Khodja Bach S; Colombeau L; Delhem N; Mordon S; Collinet P
Gynecol Obstet Fertil Senol; 2017 Apr; 45(4):190-196. PubMed ID: 28359805
[TBL] [Abstract][Full Text] [Related]
16. Folate Receptor α Expression Level Correlates With Histologic Grade in Lung Adenocarcinoma.
Driver BR; Barrios R; Ge Y; Haque A; Tacha D; Cagle PT
Arch Pathol Lab Med; 2016 Jul; 140(7):682-5. PubMed ID: 26599808
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM
Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
19. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]